Regeneron Pharmaceuticals, Inc. (BMV:REGN)
Mexico · Delayed Price · Currency is MXN | Market Cap | 1.19T +11.6% |
| Revenue (ttm) | 268.96B +5.9% |
| Net Income | 79.74B -1.7% |
| EPS | 740.23 +4.1% |
| Shares Out | n/a |
| PE Ratio | 14.97 |
| Forward PE | 13.12 |
| Dividend | 65.19 (0.60%) |
| Ex-Dividend Date | May 20, 2026 |
| Volume | n/a |
| Open | 10,836 |
| Previous Close | 10,836 |
| Day's Range | 10,836 - 10,836 |
| 52-Week Range | 9,808 - 14,276 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $REGN #BFA--Regeneron Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA.
REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings
Booking Holdings, Alphabet, and six other companies have underperformed their sectors despite improving earnings expectations, setting up potential upside during second-quarter earnings season.
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing fa...
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck...
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursda...
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing
Regeneron Pharmaceuticals Transcript: AGM 2026
The meeting approved all board proposals, including director elections, auditor ratification, and executive compensation. Strong financial growth was reported, with significant R&D investment and pipeline expansion highlighted. No shareholder questions were submitted.
Regeneron Pharmaceuticals Slides: FY 2026
Regeneron Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 12, 2026.
Regeneron Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong Q1 growth was driven by core franchises, with EYLEA HD and DUPIXENT showing momentum. The pipeline remains robust, with key catalysts expected in the second half, including regulatory and clinical milestones. Strategic flexibility in M&A and collaborations, plus a focus on IP protection and next-generation assets, position the company for long-term growth.
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare...
Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically ...
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)
Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The investigation c...
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessmen...
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or card...
Regeneron stock drops double digits on oncology trial failure
Shares of Regeneron Pharmaceuticals (REGN) fell about 12% on Monday, making the biotech company the worst-performing stock in the S&P 500 after its experimental melanoma treatment failed a pivotal lat...
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda
A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary endpoint.
Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints
Shares tumbled premarket after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
The multi-target collaboration combines Regeneron's industry-leading antibody capabilities with Parabilis' novel Helicon™ peptide platform
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines today announced a strategic research collaboration with Regeneron Pharmaceuticals, Inc. to discover and develop multiple therapeutic candidates b...
Regeneron drops after skin cancer treatment misses late-stage trial goal
Shares of Regeneron fell 11.8% premarket on Monday after the company's experimental treatment missed the main goal in a late-stage trial in patients with advanced melanoma, a type of skin cancer.
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high-...
UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc., and Society for Science (the Society) announced that Hikaru Kuribayashi , 17, of Sapporo, Japan won th...
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc., and Society for Science (the Society) announced that Hikaru Kuribayashi , 17, of Sapporo, Japan won th...
Regeneron Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Secured relief from government pricing mandates and committed $9B to U.S. R&D and manufacturing through 2030. Dupixent leads in multiple indications, with strong COPD uptake and next-gen candidates in development. EYLEA HD shows robust growth, and oncology pipeline advances with fianlimab and LIBTAYO.